Mark Cuban Extends Cost Plus Drugs Model to Rare Disease Therapies

By Elaine Chen and Andrew Joseph · STAT News · 2026-10-21

STAT News reports that the pharmaceutical startup founded by Mark Cuban is pivoting from its primary focus on generic medications to handle experimental treatments for rare conditions. This shift signals a significant expansion for Cost Plus Drugs as it attempts to apply its dire

STAT News reports that the pharmaceutical startup founded by Mark Cuban is pivoting from its primary focus on generic medications to handle experimental treatments for rare conditions. This shift signals a significant expansion for Cost Plus Drugs as it attempts to apply its dire